Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registryPasquale Paolisso, Carmine Pizzi, Luca Bergamaschi et al.|Cardiovascular Diabetology|2022Cited by 206
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT RegistryPasquale Paolisso, Emanuele Barbato, Arturo Cesaro et al.|Pharmacological Research|2022Cited by 146
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCAPasquale Paolisso, Carmine Pizzi, Alberto Foà et al.|Cardiovascular Diabetology|2021Cited by 126
Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCAPasquale Paolisso, Carmine Pizzi, Alberto Foà et al.|Cardiovascular Diabetology|2021Cited by 124
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT studyArturo Cesaro, Raffaele Marfella, Felice Gragnano et al.|Frontiers in Cardiovascular Medicine|2022Cited by 87